Retrovirus-host interactions and innate immunity to gene transfer

Retrovirus-host interactions and innate immunity to gene transfer


Group Leader

Anna Kajaste-Rudnitski


ERC logo

Innate immunity and nucleic acid sensors are involved in an increasing number of biological processes from antiviral defenses to tissue homeostasis and disease. As all current and emerging gene transfer and editing technologies expose cells to exogenous nucleic acids and/or viral vectors, we hypothesize that host antiviral factors and nucleic acid sensors play a pivotal role also in the efficacy and safety of genetic manipulation. On the other hand, the same sensors that protect us from viral infection and potentially hamper efficient gene engineering can also drive specific human autoimmune diseases when they are inappropriately activated by endogenous nucleic acids. On these premises, we study the molecular mechanisms of host-vector interplay and innate immunity in the context of gene therapy in hematopoietic stem cells (HSC) and other relevant target tissues such as the central nervous system and investigate these pathways in the context of pathological conditions of the central nervous systems and autoimmune diseases. Together, our efforts will provide insight into how nucleic acid sensing and innate immune signaling may affect efficacy and safety of gene therapy approaches in clinically relevant target cells as well as to shed light on how these same pathways may contribute to autoimmune and inflammatory pathologies.

Research activity

Our first aim is to dissect antiviral factors and innate sensing pathways in the context of genetic engineering. Building on our past work, we are addressing vector signaling and innate immune restriction across delivery platforms and in clinically relevant target cells. These basic studies of vector-host interactions will allow modulation of identified host factors or innate sensing pathways in the context of transduction or gene editing with the goal of rendering gene engineering as inert as possible, while maximizing its efficiency.

Secondly, we aim to investigate innate immunity and nucleic acid sensing in the Aicardi-Goutières Syndrome (AGS), a rare monogenic encephalopathy in which aberrant activation of innate sensing is thought to drive disease but the precise molecular mechanisms and cell types involved remain elusive. Here, we use human induced pluripotent stem cells (iPSC) harboring AGS loss of function alleles to dissect triggers of disease in cells of the central nervous system. These studies will provide insight into the pathological cascades in AGS informing the development of targeted therapies and of stealth gene engineering strategies that remain susceptible to similar mechanisms of innate sensing.